Catalog No.
DHE07702
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
IL13, NC30, Interleukin-13, IL-13
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P35225
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MILR1444A, PRO301444, CAS: 953400-68-5
Clone ID
Lebrikizumab
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER), PMID: 32909660
Adult asthma biomarkers, PMID: 24300416
Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis, PMID: 29098604
Asthma phenotypes and endotypes, PMID: 23114560
Biological therapies for atopic dermatitis: An update, PMID: 30679974
Biologics for Atopic Dermatitis, PMID: 33012322
Clinical Applications Targeting Periostin, PMID: 31037637
Commonality of the IL-4/IL-13 pathway in atopic diseases, PMID: 28277826
Current and emerging biologics for the treatment of pediatric atopic dermatitis, PMID: 33078990
Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma, PMID: 29155876
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids, PMID: 23726041
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE), PMID: 29353026
Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids, PMID: 29413502
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials, PMID: 27616196
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial, PMID: 32101256
Efficacy of biologics in atopic dermatitis, PMID: 32003247
Emerging systemic therapies for atopic dermatitis: biologics, PMID: 33045848
Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies, PMID: 29320765
Immunoglobulin interface redesigning to enhance lebrikizumab mediated immunomodulation of IL-13 hyper-response, PMID: 32448082
Innovation in Atopic Dermatitis: From Pathogenesis to Treatment, PMID: 31964499
Lebrikizumab for the treatment of asthma, PMID: 27554950
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies, PMID: 26001563
Lebrikizumab in the personalized management of asthma, PMID: 23055690
Lebrikizumab in the treatment of asthma, PMID: 27161908
Lebrikizumab treatment in adults with asthma, PMID: 21812663
Lebrikizumab treatment in adults with asthma, PMID: 22187992
Lebrikizumab treatment in adults with asthma, PMID: 22187993
Lebrikizumab treatment in adults with asthma, PMID: 22187994
Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma, PMID: 30153886
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma, PMID: 28843617
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis, PMID: 31395084
New and Emerging Systemic Treatments for Atopic Dermatitis, PMID: 32519223
New and Emerging Therapies for Pediatric Atopic Dermatitis, PMID: 31364023
New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!, PMID: 28583618
New perspectives of childhood asthma treatment with biologics, PMID: 30444939
Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis, PMID: 32525769
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis, PMID: 33008934
Profile of lebrikizumab and its potential in the treatment of asthma, PMID: 26309415
Relative efficacy of systemic treatments for atopic dermatitis, PMID: 30296535
Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab, PMID: 28238745
Selective IL-13 inhibitors for the treatment of atopic dermatitis, PMID: 33889195
Specific Immune Response to Phospholipase B-Like 2 Protein, a Host Cell Impurity in Lebrikizumab Clinical Material, PMID: 27739010
Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab, PMID: 23357170
Tailored therapy for severe asthma, PMID: 25671117
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge, PMID: 24131304
The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma, PMID: 31866859
Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis, PMID: 32104006
Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches, PMID: 30825336
Update in asthma 2011, PMID: 22753688
What's New in Atopic Dermatitis, PMID: 30850043
For research use only. Not for human or drug use.
